EVALI Meta-Analysis: 94% Hospitalization Rate, Bilateral Lung Damage in Nearly All Cases

Vaping feels routine to millions of adolescents and young adults, but a new meta-analysis published in BMC Pulmonary Medicine on May 16, 2026 quantifies just how badly it can go wrong. Jurado-Hernández et al. pooled data from 38 studies and 13,516 patients diagnosed with e-cigarette or vaping product use-associated lung injury (EVALI), producing the most comprehensive statistical portrait of the condition to date. The headline numbers are striking: nearly every hospitalized patient showed bilateral lung damage on imaging, and more than one in three required intensive care.

EVALI clinical profile across 13,516 patients

The systematic review and meta-analysis found that EVALI presents with a wide but recognizable cluster of symptoms. Constitutional symptoms, things like fever, chills, and weight loss, appeared in 87.3% of patients. Respiratory symptoms were nearly as common at 87.1%, and gastrointestinal complaints such as nausea and vomiting affected 77.1%. Breaking those categories down further: shortness of breath appeared in 82.7% of cases, dyspnea in 81.2%, fever in 79.9%, cough in 77.4%, and nausea or vomiting in 75.0%.

This overlapping symptom profile is one reason EVALI is easy to miss on first presentation. As the CDC's interim guidance on EVALI diagnosis notes, the condition mimics influenza, pneumonia, and other acute respiratory illnesses, making a careful history of vaping use essential before imaging or lab work can confirm the diagnosis.

The population in this analysis skewed young and male, consistent with who is most likely to vape. Most patients had been vaping for more than three months before symptoms appeared, based on the ten studies that reported that detail, suggesting that lung injury from vaping is rarely an immediate reaction.

Hospitalization and ICU burden among young vapers

The severity data should reframe how clinicians and parents think about vaping as a low-stakes habit. Hospitalization was required in 94.4% of cases across the studies that reported admissions data. Of all patients, 35.7% needed intensive care unit admission, a number that reflects how rapidly EVALI can progress to respiratory failure.

Overall mortality was 0.9% across 10,635 patients, with minimal variation between studies. That figure sounds reassuring, but it obscures the acute suffering involved: a condition that sends 94 out of every 100 patients to the hospital and more than a third to intensive care is not mild simply because most people survive it. The 2019 to 2020 EVALI outbreak was already known to disproportionately harm young people, strongly linked to vaping THC-containing products adulterated with vitamin E acetate, and this meta-analysis confirms that the clinical burden remained heavy through 2022.

For adolescents in particular, an ICU stay carries costs beyond the immediate medical episode. Research on long-term outcomes in EVALI survivors has found that despite acute recovery, nearly half of patients report persistent respiratory symptoms a year later, alongside meaningful rates of cognitive impairment, depression, anxiety, and post-traumatic stress.

How the research team built a pooled estimate

The authors searched five major databases: Medline/PubMed, Scopus, Web of Science, Embase, and the Virtual Health Library, covering publications up to November 2024. They restricted inclusion to observational studies that diagnosed EVALI using the Centers for Disease Control and Prevention case definition, which requires e-cigarette use within the prior 90 days, pulmonary infiltrates on imaging, and the exclusion of other etiologies, as StatPearls' EVALI overview details.

Of 38 studies that met full-text criteria, 36 came from the United States and 2 from Canada, with patients diagnosed between 2019 and 2022. To calculate pooled prevalence estimates for clinical symptoms and radiological findings, the team used a random-effects model with Freeman-Tukey double arcsine transformation, a technique that stabilizes variance when individual proportions approach zero or one, as several EVALI imaging rates do.

The geographic concentration of included studies is worth noting: EVALI was first recognized as a syndrome in the United States, and the bulk of systematic case reporting happened there. Studies from other countries were scarce enough to be excluded, which shapes how broadly these numbers can be generalized.

Radiological findings and study limitations

On imaging, bilateral pulmonary involvement appeared in 98.1% of cases and ground-glass opacities in 94.9%. Ground-glass opacities, areas of hazy increased lung density that preserve underlying bronchial and vascular detail, are a hallmark of several inflammatory lung conditions and are not unique to EVALI, which is part of why clinical history remains central to diagnosis.

The study has important limitations. Most of the underlying data came from the peak of the EVALI outbreak in 2019 and 2020, so the findings may not fully reflect how the condition presents today, when product formulations and regulatory environments have changed. CDC surveillance data tracked EVALI cases in near real-time using emergency department syndromic data during the outbreak; that kind of granular ongoing monitoring is harder to replicate in a retrospective meta-analysis. Additionally, because randomized trials of EVALI are not feasible, all 38 included studies were observational, introducing potential selection and reporting biases.

The heterogeneity of case definitions across studies, even when anchored to the CDC criteria, also introduces variability. Some studies captured only hospitalized patients, which likely inflates hospitalization and ICU rates relative to what a complete population of vapers who develop lung symptoms would show.

What the EVALI findings mean for prevention and clinical practice

The practical message from this analysis is that early recognition matters enormously. A young patient presenting with a combination of fever, dyspnea, cough, and nausea should trigger a direct question about vaping, and a positive history should prompt imaging without delay. Bilateral ground-glass opacities on CT in that context are strong evidence of EVALI.

The CDC archive on the EVALI outbreak notes that new case counts declined after September 2019, largely attributed to the removal of vitamin E acetate from many THC cartridges, but monitoring via emergency department data continues because new product formulations keep entering the market. That surveillance infrastructure is precisely what future research will depend on if the syndrome resurfaces in a different form.

For now, this meta-analysis offers clinicians a reliable baseline: EVALI hits hard, hits fast, and hits young. A 0.9% mortality rate masks a condition that demands hospital-level care in almost every case it is recognized.